Denali Therapeutics (NASDAQ:DNLI) is a top mid-cap healthcare stock under $50. Wedbush analyst Laura Chico maintains a Buy rating with a $30 target price, implying a 78% upside. The company completed a $200 million secondary offering, issuing 9.1 million common shares at $17.50 each. All 11 analysts rate DNLI a Buy with a median 1-year price target of $31, an 84% potential upside.

Denali Therapeutics (NASDAQ:DNLI) uses its TransportVehicle™ platform to develop treatments for neurodegenerative diseases. Despite its potential, some believe other AI stocks offer greater upside with lower risk. For those seeking undervalued AI stocks with growth potential, consider exploring other options beyond DNLI.

Investors are advised to consider other AI stocks that may offer better upside potential and less downside risk than Denali Therapeutics (NASDAQ:DNLI). While DNLI is a promising investment, exploring other opportunities in the AI sector could provide a more favorable risk-reward ratio for investors looking to capitalize on emerging trends.

Read more at Yahoo Finance: Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50?